Compare Bristol-Myers Squibb Co (BMY) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs FedEx Corporation — how do they compare? Bristol-Myers Squibb Co trades at $63.97 (market cap $129.94B), while FedEx Corporation trades at $326.4 (market cap $76.28B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | FDX | |
|---|---|---|
Market Cap | $129.94B | $76.28B |
Sector | Health | Industrials |
52-Week High | $65.89 | $338.75 |
52-Week Low | $42.60 | $180.51 |
Enterprise Value | $163.92B | $105.91B |
Dividend Yield | 3.96% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
FedEx (FDX) trades at $326.25, up 0.36% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $360.27. Recent earnings beats in Q4 2025 and Q1 2026 highlight strong profitability, with a net income margin of 4.68% and ROE of 14.82%. The company's Network 2.0 initiative aims for $2 billion in annual savings, driving efficiency gains amid a shift to premium logistics services.
The stock offers upside potential from cost-cutting and freight recovery, but faces risks from competitive pressures and economic sensitivity. Analysts are predominantly bullish (57% buy ratings), though elevated RSI levels suggest near-term overbought conditions. Long-term growth hinges on execution of margin improvements and volume normalization in the LTL market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
